Home | Regulatory Tracker | DSIP
DSIP (emideltide)
Nomination withdrawn
as of October 2026
By Stephen Kimball, 26+ years researching the health, wellness, supplement, and peptide industries
As of October 2026, DSIP isn’t approved for any use and can’t be legally compounded. It left FDA’s safety-risk list in April 2026 only because its nominators withdrew, and FDA’s page still says the agency hasn’t found safety information for the proposed route. In July 2026, DSIP was the one peptide of seven that FDA’s advisory panel did not recommend: the reported vote was 6 yes, 7 no, 1 abstention. FDA’s own reviewers had also advised against it. Anything sold as DSIP today comes from the “research use only” market.
Sources
Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks (withdrawn table — "Emideltide (DSIP)")
U.S. Food & Drug Administration
dated Apr 2026
FDA Briefing Document — Emideltide-Related Bulk Drug Substances
U.S. Food & Drug Administration
dated Jul 2026
Change log
2023
FDA places emideltide in Category 2.
April 2026
Moves to FDA’s “nominated but withdrawn” table.
July 2026
FDA staff briefing proposes that emideltide NOT be added.
July 24, 2026
Advisory panel reportedly votes 6–7 (1 abstention): not recommended, for opioid withdrawal, chronic insomnia, and narcolepsy.